探索Cistanche在喘治疗中的治疗潜力和分子机制
Jiliu Liu1, Jie Gao1, Anying Xiong1
1School of Medicine, Southwest Jiaotong University, Laboratory of Allergy and Precision Medicine, Chengdu Institute of Respiratory Health, Affiliated Hospital of Southwest Jiaotong University, the Third People's Hospital of Chengdu, Chengdu 610031, China; Department of Respiratory Medicine, Chengdu Third People's Hospital Branch of National Clinical Research Center for Respiratory Disease, Affiliated Hospital of ChongQing Medical University, Chengdu 610031, China.
概括
传统草药西斯坦奇通过向炎症和免疫反应,有效地减少小鼠的喘症状. 这种天然化合物显示出作为喘管理的补充治疗的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 基因组学就是基因组学.
背景情况:
- 喘是一种慢性呼吸道疾病,对全球健康产生重大影响.
- 目前的喘治疗方法,如皮质类固醇,具有局限性,包括可变的疗效和副作用.
- 需要新的治疗策略,包括天然产品,用于喘管理.
研究的目的:
- 为了研究Cistanche在室内灰尘 (HDM) 诱导的喘小鼠模型中的治疗潜力.
- 为了阐明Cistanche抗喘作用背后的分子机制.
- 确定Cistanche在喘中的关键活性成分和治疗点.
主要方法:
- 室内灰尘虫 (HDM) 诱导的喘小鼠模型.
- 转录组学,权重基因共同表达网络分析 (WGCNA) 和基因组丰富分析 (GSEA).
- 液态染色学-高分辨率质谱学 (LCHRMS) 和分子对接.
主要成果:
- 在喘小鼠中,喘治疗显著降低了呼吸道过敏反应,炎症和粘液产生.
- 转录组分析显示,Cistanche调节IL-4,IL-5和与乙氨基酸相关的通路,并参与葡萄糖皮质体过程.
- 皮诺雷西诺4-O-Beta-D-Glucopyranoside (PG) 被确定为关键成分,准PI3K-AKT通路并降低调节可诱导的氧化合成酶 (iNOS).
结论:
- 西斯坦奇通过调节免疫反应和向关键喘相关途径和蛋白质,在喘中表现出显著的治疗效果.
- 该研究强调了Cistanche,特别是其成分PG,作为喘潜在的替代或补充疗法.
- 需要进一步的临床研究来验证Cistanche的疗效,并将其整合到喘管理策略中.
相关概念视频
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
218
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
218
01:24Antiasthma Drugs: Methylxanthines
195
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
195
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
01:19Antiasthma Drugs: Leukotriene Modifiers
245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
245
01:20Asthma: Pathogenesis and Management
351
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
351
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
240
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
240